# Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

> **NCT06957366** · NA · RECRUITING · sponsor: **McMaster University** · enrollment: 920 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)
- VTE

## Interventions

- **OTHER:** PAUSE Perioperative DOAC Management
- **OTHER:** ASRA Perioperative DOAC Management

## Key facts

- **NCT ID:** NCT06957366
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 920 (ESTIMATED)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06957366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06957366, "Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06957366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*